By using triple‐transgenic Alzheimer's disease (AD) mice, Xiubo Du and co‐workers demonstrate that Se‐methylselenocysteine (SMC) is powerful in ameliorating AD‐related neuropathology and cognitive deficits via modulating oxidative stress, metal homeostasis, and extracellular signal‐regulated kinase (ERK) activation. The study, described in article number 1800107, suggests that SMC is a promising compound for the prevention or intervention of AD.
